Uncertainties in cardiovascular risk factors : sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity?
The clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where the recommendations are not supported by solid evidence. In the fifth National Congress Grey Zones held in Bergamo in June 2022, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies regarding cardiovascular risk factors. The manuscript represents the organization of the meeting, with an initial revision of the present guidelines on this topic, followed by an expert presentation of pros (White) and cons (Black) related to the identified "gaps of evidence". For every issue is then reported the "response" derived from the votes of the experts and the public, the discussion and, finally, the highlights, which are intended as practical "take home messages" to be used in the everyday clinical practice. The first gap in evidence discussed is the indication for therapy with sodium-glucose cotransporter 2 (SGLT2) inhibitors for all diabetic patients at high cardiovascular risk. The second examines the possibility of using SGLT2 inhibitors in all patients with renal insufficiency, regardless of albuminuria. The last gap in evidence regards the possible use of glucagon-like peptide-1 receptor agonists as a weapon against obesity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Giornale italiano di cardiologia (2006) - 24(2023), 5 vom: 27. Mai, Seite 337-343 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Incertezze nei fattori di rischio cardiovascolare: inibitori del cotrasportatore sodio-glucosio di tipo 2 per tutti i pazienti diabetici ad elevato rischio cardiovascolare e per tutti i pazienti con insufficienza renale indipendentemente dall’albuminuria? Agonisti del recettore del glucagon-like peptide-1 come arma contro l’obesità? |
|---|
| Beteiligte Personen: |
Avogaro, Angelo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9NEZ333N27 |
|---|
| Anmerkungen: |
Date Completed 02.05.2023 Date Revised 02.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1714/4026.40007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356059626 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356059626 | ||
| 003 | DE-627 | ||
| 005 | 20231226065645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1714/4026.40007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356059626 | ||
| 035 | |a (NLM)37102346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Avogaro, Angelo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uncertainties in cardiovascular risk factors |b sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity? |
| 246 | 3 | 3 | |a Incertezze nei fattori di rischio cardiovascolare: inibitori del cotrasportatore sodio-glucosio di tipo 2 per tutti i pazienti diabetici ad elevato rischio cardiovascolare e per tutti i pazienti con insufficienza renale indipendentemente dall’albuminuria? Agonisti del recettore del glucagon-like peptide-1 come arma contro l’obesità? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2023 | ||
| 500 | |a Date Revised 02.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where the recommendations are not supported by solid evidence. In the fifth National Congress Grey Zones held in Bergamo in June 2022, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies regarding cardiovascular risk factors. The manuscript represents the organization of the meeting, with an initial revision of the present guidelines on this topic, followed by an expert presentation of pros (White) and cons (Black) related to the identified "gaps of evidence". For every issue is then reported the "response" derived from the votes of the experts and the public, the discussion and, finally, the highlights, which are intended as practical "take home messages" to be used in the everyday clinical practice. The first gap in evidence discussed is the indication for therapy with sodium-glucose cotransporter 2 (SGLT2) inhibitors for all diabetic patients at high cardiovascular risk. The second examines the possibility of using SGLT2 inhibitors in all patients with renal insufficiency, regardless of albuminuria. The last gap in evidence regards the possible use of glucagon-like peptide-1 receptor agonists as a weapon against obesity | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 650 | 7 | |a SLC5A2 protein, human |2 NLM | |
| 650 | 7 | |a serum sodium transport inhibitor |2 NLM | |
| 700 | 1 | |a Corsini, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Sinagra, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Borghi, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Sciatti, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Trevisan, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Fioretto, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrò, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Di Pasquale, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Senni, Michele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di cardiologia (2006) |d 2006 |g 24(2023), 5 vom: 27. Mai, Seite 337-343 |w (DE-627)NLM16119561X |x 1972-6481 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:5 |g day:27 |g month:05 |g pages:337-343 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1714/4026.40007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 5 |b 27 |c 05 |h 337-343 | ||